CJC-1295 (no-DAC) + Ipamorelin Blend Pharmacokinetics
CJC-1295 (no-DAC) + Ipamorelin Blend half-life, absorption, routes of administration, and clearance.
Extended Half-Life Through Albumin Binding
DAC technology represents a significant pharmacological advancement. After subcutaneous injection, CJC-1295 with DAC forms a covalent bond with circulating albumin through a reactive maleimido group, protecting the peptide from enzymatic degradation and renal clearance. Research confirmed an estimated half-life of 5.8–8.1 days in healthy adults.
CJC-1295
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog available in two forms: with DAC (Drug Affinity Complex) for extended half-life, and without DAC (MOD GRF 1-29) for more pulsatile release.
The study of doping market: How to produce intelligence from Internet forums.
Analysis of 13 Internet forums identified 327 doping suppliers and detected emerging peptide products including CJC-1295. CJC-1295 demonstrated extended plasma half-life and sustained GH secretion in rats compared to native GRF.
Physicochemical and PK profile
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
References
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. · Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. · Teichman SL, Neale A, Lawrence B et al. · 2006
- Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561. · Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW · 1998
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. · Gobburu JV, Agersø H, Jusko WJ et al. · 1999
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006. · Zaidi D, James KA, Wagner GF · 2006
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. · Ionescu M, Frohman LA · 2006